



## **Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference**

January 4, 2021

DURHAM, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that Matt Kane, Co-founder and Chief Executive Officer and Derek Jantz, Ph.D., Co-Founder and Chief Scientific Officer, will present at the 39<sup>th</sup> Annual J.P. Morgan Healthcare Conference taking place virtually from January 11-14, 2021.

Details for the company presentation are as follows:

### **39<sup>th</sup> Annual J.P. Morgan Healthcare Conference**

Date: Wednesday, January 13, 2021

Time: 2:00 - 2:40 p.m. ET

A live webcast of the presentation will be accessible on the Company's website, [www.precisionbiosciences.com](http://www.precisionbiosciences.com), in the Investors & Media section under Events and Presentations. An archived replay of the webcasts will be available for approximately 30 days following the presentations.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

### **Investor Contact:**

Alex Kelly

Interim Chief Financial Officer

[Alex.Kelly@precisionbiosciences.com](mailto:Alex.Kelly@precisionbiosciences.com)

### **Media Contact:**

Maurissa Messier

Senior Director, Corporate Communications

[Maurissa.Messier@precisionbiosciences.com](mailto:Maurissa.Messier@precisionbiosciences.com)